Supplementary_Fig1.jpg (1.04 MB)

Interpatient variability in mesothelin (MSLN) expression necessitates its evaluation before gastric cancer immunotherapy. Supplementary figure

figure

posted on 2022-03-24, 08:53 authored by Mahmood Naderi, Nasim Sajadi, Bahareh Sharififard, Ramin Shakeri, Vahid Mansouri, Masoud Sotoudeh

Supplementary Figure 1. A few representative cores showing percent positivity of MSLN in tumor cells

History

Usage metrics

Categories

Keywords

stomach neoplasm stomach cancer gastric cancer immunotherapy antigenic targets mesothelin MSLN gastric adenocarcinoma

Licence

CC BY-NC-ND 4.0

Exports